Market Cap 23.06M
Revenue (ttm) 1.32M
Net Income (ttm) -34.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,584.09%
Debt to Equity Ratio 0.00
Volume 40,500
Avg Vol 1,766,656
Day's Range N/A - N/A
Shares Out 10.41M
Stochastic %K 62%
Beta 0.53
Analysts Strong Sell
Price Target $9.60

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology
Sector: Healthcare
Phone: 605 679 6980
Address:
777 W 41st St., Miami Beach, United States
JTebow_CWS
JTebow_CWS Aug. 24 at 7:59 PM
$SABS Another board member William J. Polvino, M.D https://bridgemedicines.com/press-releases/bridge-medicines-appoints-william-j-polvino-m-d-as-chief-executive-officer/
1 · Reply
JTebow_CWS
JTebow_CWS Aug. 24 at 7:53 PM
$SABS Another Director Go Hurricanes. https://www.um-jmhendocrinology.com/jay-s-skyler-md
1 · Reply
JTebow_CWS
JTebow_CWS Aug. 23 at 2:10 AM
$SABS $SABSW Thoughts?
1 · Reply
DDiamond_Handz
DDiamond_Handz Aug. 22 at 7:13 PM
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 21 at 2:28 AM
$SABS John Wentworth MBBS, FRACP, Professor of Medicine in Australia. Another Clinical Board member on SAB BIO. He’s seems to be talking about TZIELD that delays Type 1 by 2 years. I’m thankful we may finally be on a path to permanently delay this horrible child onset disease. https://youtu.be/K_L_Td3KW3g?si=GhhfsWmjfJT4zjQW
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 6:34 PM
$SABS Miami has been known recognized leader in research for a long time. Jay S. Skyler, MD, MACP is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida https://diabetesresearch.org/jay-skyler/
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 6:30 PM
$SABS Belgium lead endocrinologist on SAB BIO clinical board. https://www.diabetestechnology.org/dtm/bios/2022/mathieu.html
2 · Reply
DDiamond_Handz
DDiamond_Handz Aug. 20 at 6:21 PM
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 1:13 PM
$SABS USA, Great Britain, and Australia researchers on this project. https://www.svi.edu.au/researchers/professor-tom-kay/
1 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 1:10 PM
$SABS Another founding clinical board member. https://diabetes.ucsf.edu/people/stephen-gitelman
0 · Reply
Latest News on SABS
SAB BIO Announces Oversubscribed $175 Million Private Placement

Jul 21, 2025, 7:30 AM EDT - 5 weeks ago

SAB BIO Announces Oversubscribed $175 Million Private Placement


SAB BIO Reports Full Year 2024 Operating and Financial Results

Mar 31, 2025, 7:32 AM EDT - 5 months ago

SAB BIO Reports Full Year 2024 Operating and Financial Results


SAB BIO to Participate in Upcoming Investor Conferences

Jan 31, 2025, 7:00 AM EST - 7 months ago

SAB BIO to Participate in Upcoming Investor Conferences


Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 3:40 PM EST - 7 months ago

Why Is SAB BIO Stock Trading Lower On Tuesday?


SAB BIO Appoints Lucy To as Chief Financial Officer

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer


SAb Biotherapeutics Rebrands as SAB BIO

Jun 20, 2024, 7:20 AM EDT - 1 year ago

SAb Biotherapeutics Rebrands as SAB BIO


SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 16, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Provides SAB-142 Trial Update


SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 8, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting


SAB Biotherapeutics Announces Executive Leadership Change

Feb 2, 2024, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Executive Leadership Change


SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Jan 2, 2024, 4:30 PM EST - 1 year ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split


JTebow_CWS
JTebow_CWS Aug. 24 at 7:59 PM
$SABS Another board member William J. Polvino, M.D https://bridgemedicines.com/press-releases/bridge-medicines-appoints-william-j-polvino-m-d-as-chief-executive-officer/
1 · Reply
JTebow_CWS
JTebow_CWS Aug. 24 at 7:53 PM
$SABS Another Director Go Hurricanes. https://www.um-jmhendocrinology.com/jay-s-skyler-md
1 · Reply
JTebow_CWS
JTebow_CWS Aug. 23 at 2:10 AM
$SABS $SABSW Thoughts?
1 · Reply
DDiamond_Handz
DDiamond_Handz Aug. 22 at 7:13 PM
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 21 at 2:28 AM
$SABS John Wentworth MBBS, FRACP, Professor of Medicine in Australia. Another Clinical Board member on SAB BIO. He’s seems to be talking about TZIELD that delays Type 1 by 2 years. I’m thankful we may finally be on a path to permanently delay this horrible child onset disease. https://youtu.be/K_L_Td3KW3g?si=GhhfsWmjfJT4zjQW
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 6:34 PM
$SABS Miami has been known recognized leader in research for a long time. Jay S. Skyler, MD, MACP is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida https://diabetesresearch.org/jay-skyler/
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 6:30 PM
$SABS Belgium lead endocrinologist on SAB BIO clinical board. https://www.diabetestechnology.org/dtm/bios/2022/mathieu.html
2 · Reply
DDiamond_Handz
DDiamond_Handz Aug. 20 at 6:21 PM
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 1:13 PM
$SABS USA, Great Britain, and Australia researchers on this project. https://www.svi.edu.au/researchers/professor-tom-kay/
1 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 1:10 PM
$SABS Another founding clinical board member. https://diabetes.ucsf.edu/people/stephen-gitelman
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 11:14 AM
$SABS https://ufhealth.org/doctors/michael-j-haller/bio
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 11:12 AM
$SABS One of the Board Members on SAB BIO. https://profiles.cardiff.ac.uk/staff/dayancm
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 12:58 AM
$SABS Not going bankrupt anytime soon. Peter Lynch said, it’s hard to go bankrupt when you don’t have any debt.
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 20 at 12:53 AM
$SABS Powerhouse Diabetes team. World leaders on diabetes in this list.
1 · Reply
stockboyaisle1
stockboyaisle1 Aug. 19 at 8:39 PM
0 · Reply
Nicks_pics
Nicks_pics Aug. 19 at 4:55 AM
$SABS Has to be the quietist feed on ST.
0 · Reply
DDiamond_Handz
DDiamond_Handz Aug. 12 at 1:56 PM
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 10 at 11:33 PM
$SABS Still an amazing educational podcast on Polyclonal antibodies. https://podcasts.apple.com/us/podcast/welcome-to-the-arena-from-icr-conversations-with/id1575848987?i=1000605311917
1 · Reply
NextRunnerTV
NextRunnerTV Aug. 8 at 6:54 AM
🚨 ATTENTION ON $IBG 🚨 Nearly HALF the float is now held short. 💥 No dilution. Cash flow positive. Setup is explosive. 🔥 WATCH THIS VIDEO ⬇️ https://www.tiktok.com/@nextrunnertv/video/7532181249314671886?is_from_webapp=1&sender_device=pc&web_id=7508604446427924010 $ZURA $SABS $ADTX $INBS $INTS
0 · Reply
JTebow_CWS
JTebow_CWS Aug. 8 at 1:24 AM
$SABS FDA is finally being transparent about what is needed for future approvals. No more guessing. In May 2025, SAB BIO had a Type B meeting with the United States Food and Drug Administration (FDA) where the Company received Agency feedback and aligned on the progression and design of SAB-142’s SAFEGUARD study, which is estimated to initiate in Q3 2025. Following the meeting, the company confirmed plans to use this study as supportive evidence for future regulatory approvals.
0 · Reply
Goatcheese
Goatcheese Aug. 7 at 5:38 PM
$SABS patience
0 · Reply
stockboyaisle1
stockboyaisle1 Aug. 7 at 3:50 PM
$SABS https://ir.sab.bio/news-releases/news-release-details/sab-bio-reports-second-quarter-financial-results-and-highlights/
0 · Reply